Hillstream Biopharma (NASDAQ:CNTN) Director Gary Stetz Sells 12,500 Shares of Stock

Posted by on May 28th, 2026

Hillstream Biopharma Inc. (NASDAQ:CNTN – Get Free Report) Director Gary Stetz sold 12,500 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $3.47, for a total value of $43,375.00. Following the transaction, the director owned 134,175 shares of the company’s stock, valued at approximately $465,587.25. The trade was a 8.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Hillstream Biopharma Stock Performance

Shares of CNTN opened at $3.23 on Thursday. The company has a market cap of $225.47 million, a P/E ratio of -2.81 and a beta of 1.44. The stock’s fifty day moving average is $3.33. Hillstream Biopharma Inc. has a 12 month low of $1.08 and a 12 month high of $9.08.

Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) EPS for the quarter.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Weiss Ratings downgraded Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th. Wall Street Zen upgraded Hillstream Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on CNTN

About Hillstream Biopharma

(Get Free Report)

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.

Read More

Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.